# Zymvol Biomodeling SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zymvol-biomodeling-sl

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.zymvol.com
- Total disclosed funding: $4.6M
- Latest round: Seed (Feb 12, 2025)
- Investors on record: 3

## About

Based in Delaware, US, and co-founded by Francisco Morís, Simon Sheld, and Juan Pablo Bermúdez in 2017, Zymvol Biomodeling, SL operates as a biotechnology company specializing in bioinformatics and molecular modeling to accelerate enzyme discovery and design. The company mainly serves to pharmaceutical, chemical, and biotech industries. In February 2025, Zymvol Biomodeling SL raised EUR 3 million in seed funding led by new investor Faber Ventures, with participation from another new investor Übermorgen Ventures. Returning investor Elaia Partners also participated in the round. The company provides computational enzyme engineering for industrial applications by leveraging algorithms and machine learning techniques. The company helps to identify and engineer enzymes with improved performance characteristics such as higher activity, specificity, and stability. Other services offered by Zymvol include In Silico Design to custom design enzymes in less than a month, ZymQuest to improve the active site and long-range positions of the enzyme, and experimental validation. The company will use the February 2025 funding to expand the startup's experimental laboratory, located in the Barcelona Science Park.

## Funding rounds

- Seed, Feb 12, 2025, $3.1M — Elaia Partners, Faber Ventures, Ubermorgen Ventures
- Seed, Feb 10, 2023, $1.5M — Elaia Partners

## Investors

- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Seed
- Faber Ventures (https://capitalatlas.ai/funds/faber-ventures) — Seed
- Ubermorgen Ventures (https://capitalatlas.ai/funds/ubermorgen-ventures) — Seed